Genmab A/S Announces Data From Its Phase 3 LiGeR-HN1 Study Of Petosemtamab Demonstrates 50% Death Risk Reduction For Treatment Of Head And Neck Squamous Cell Carcinoma
Genmab A/S (NASDAQ:GMAB) today announced positive topline results from the global Phase 3 LiGeR-HN1 trial (NCT06525220) evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth
Genmab's new cancer medicine cut death risk in half in testing. When a company shows strong medicine results, watch if doctors start using it widely.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.